title: Management of BCC and SCC of the Head and Neck.
abstract: BACKGROUND
  For decades radiotherapy (RT) has been shown to treat skin cancers; however, the indications, delivery methods, and techniques for RT continue to evolve.
  
  
  METHODS
  Relevant prospective and retrospective reports were reviewed that addressed outcomes with, indications for, and delivery techniques used with RT for the management of cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the head and neck.
  
  
  RESULTS
  Rates of local control higher than 90% are typically achievable for early-stage BCC and SCC of the head and neck. RT is often recommended for tumors located in cosmetically or functionally sensitive areas of the face, for patients who cannot tolerate anesthesia, for those taking anticoagulants, or for patients who prefer RT to other treatment options. A wide range of radiation doses, daily fractionation schedules, and radiation techniques have been shown to be effective for management. In general, postoperative local radiation is recommended following excision for patients with high-risk factors, including those whose tumors have close or positive margins, perineural invasion, invasion of the bone or nerves, or those with recurrent disease.
  
  
  CONCLUSIONS
  RT plays an integral role in the treatment of primary and postoperative cutaneous BCC and SCC of the head and neck. Prospective trials are in progress to address the roles of concurrent systemic therapy and RT for both cutaneous BCC and SCC.
authors.affiliation: Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Louis.Harrison@Moffitt.org.
authors.forename: Tobin J
authors.initials: TJ
authors.lastname: Strom
authors.forename: Jimmy J
authors.initials: JJ
authors.lastname: Caudell
authors.forename: Louis B
authors.initials: LB
authors.lastname: Harrison
mesh_terms: D002280:Basal Cell Carcinoma / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors